Transgene SA (FRA:TGNA)

Market Cap	205.37M +131.9%
Revenue (ttm)	7.21M +13.5%
Net Income	-37.52M
EPS	-0.26
Shares Out	n/a
PE Ratio	n/a
Forward PE	n/a
Dividend	n/a
Ex-Dividend Date	n/a

Volume	n/a
Average Volume	333
Open	0.6940
Previous Close	0.7160
Day's Range	0.6940 - 0.6940
52-Week Range	0.5500 - 1.4850
Beta	n/a
RSI	36.35
Earnings Date	Mar 24, 2026

About Transgene

Transgene SA, a biotechnology company, designs and develops therapeutic vaccines and oncolytic viruses for the treatment of cancer in France. It involved in developing TG4050, a therapeutic vaccine that is in Phase II clinical trial for the treatment of ovarian cancer, and head and neck cancers; TG4001, a therapeutic vaccine, which is in Phase II clinical trial for the treatment of human papillomavirus (HPV 16) positive cancers; TG6002, an oncolytic virus that is in Phase I/IIa clinical trial for the treatment of solid tumors, including gastroi...

• Industry: Biological Products, Except Diagnostic Substances
• Founded: 1979
• Employees: 147
• Stock Exchange: Frankfurt Stock Exchange
• Ticker Symbol: TGNA

Financial Performance

In 2025, Transgene's revenue was 7.21 million, an increase of 13.49% compared to the previous year's 6.35 million. Losses were -37.52 million, 10.5% more than in 2024.